Featured Research

from universities, journals, and other organizations

New Stomach Cancer Therapy Potentially More Convenient And Better Tolerated

Date:
May 19, 2005
Source:
University of Southern California
Summary:
A new combination chemotherapy appears to battle advanced stomach cancer harder than other platinum-based therapies, while offering patients more convenience and potentially less discomfort.

ORLANDO, Fla.-A new combination chemotherapy appears to battle advanced stomach cancer harder than other platinum-based therapies, while offering patients more convenience and potentially less discomfort, according to results announced at the 2005 Annual Meeting of the American Society of Clinical Oncology.

Researchers studied the combination of a new drug, called S-1, and the platinum-based chemotherapy called cisplatin in patients with advanced gastric cancer.

Overall, 13 of the 20 patients (65 percent) evaluated so far in the phase II trial responded to the chemotherapy. That means tumors shrank in response to the drug.

"We believe the therapy has the potential to not only fight cancer more effectively, but also is easier for cancer patients to deal with," says study co-author and medical oncologist Heinz-Josef Lenz, M.D., associate professor of medicine at the Keck School of Medicine of the University of Southern California and USC/Norris Comprehensive Cancer Center.

The study was presented at ASCO by Jaffer A. Ajani, M.D., professor in gastrointestinal medical oncology at University of Texas/M.D. Anderson Cancer Center.

In 2005, experts estimate that 21,860 Americans will be diagnosed with stomach cancer during 2005 and another 11,550 will die from the disease.

In addition to surgery, physicians today use a variety of chemotherapy drugs against stomach cancer. Yet researchers have not found a standard chemotherapy regimen that dramatically improves survival more than any other.

One commonly used drug is the traditional chemotherapy called 5-FU (5-fluorouracil). Studies have shown that when cisplatin is combined with 5-FU, cancer shrinks in 46 percent to 51 percent of stomach cancer patients. The combination of S-1 and cisplatin aims to take that a step further.

S-1 consists of a number of parts. One portion of S-1 actually breaks down into 5-FU in the body. At the same time, it contains another element that keeps levels of 5-FU fairly steady in the body, reducing the ups and downs of chemotherapy. It contains a third element, too, that fights 5-FU's toxic effects in gastrointestinal tissues-a cause of chemotherapy nausea and vomiting. Finally, it is available in a capsule, instead of through an intravenous infusion, making it more convenient for patients.

In this study, patients received an infusion of cisplatin on the first day of treatment, then took S-1 twice a day every day for three weeks, and took a week off to recover before starting the cycle all over again.

In all, 41 patients participated and were evaluable; researchers have examined information on the drug's safety in 30 patients and on the drug's effectiveness in 20 patients. In the 13 patients whose cancer responded to the drug, tumors began growing again about 4.8 months after treatment.

Lenz is optimistic about the drug's potential. "At USC/Norris, we established the genetic profile giving the rationale for this drug, so we understand how and why it works," he says. He noted that another early study in Japan of S-1 and cisplatin for advanced gastric cancer showed 19 of 25 patients, or 76 percent, responded to the drug.

The most common side effects were fatigue, nausea and anorexia.

S-1 is under development by Taiho Pharma USA Inc.

###

L.B. Saltz, H. Lenz, H. Hochster, S. Wadler, P. Hoff, N. Kemeney, E. Hollywood, M. Gonen, S. Wetherbee, H. Chen, "Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer," 2005 Annual Meeting of the American Clinical Oncology. Gastrointestinal cancer poster session.


Story Source:

The above story is based on materials provided by University of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University of Southern California. "New Stomach Cancer Therapy Potentially More Convenient And Better Tolerated." ScienceDaily. ScienceDaily, 19 May 2005. <www.sciencedaily.com/releases/2005/05/050519065631.htm>.
University of Southern California. (2005, May 19). New Stomach Cancer Therapy Potentially More Convenient And Better Tolerated. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2005/05/050519065631.htm
University of Southern California. "New Stomach Cancer Therapy Potentially More Convenient And Better Tolerated." ScienceDaily. www.sciencedaily.com/releases/2005/05/050519065631.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com
How to Master Motherhood With the Best Work/Life Balance

How to Master Motherhood With the Best Work/Life Balance

TheStreet (Apr. 22, 2014) In the U.S., there are more than 11 million couples trying to conceive at any given time. From helping celebrity moms like Bethanny Frankel to ordinary soon-to-be-moms, TV personality and parenting expert, Rosie Pope, gives you the inside scoop on mastering motherhood. London-born entrepreneur Pope is the creative force behind Rosie Pope Maternity and MomPrep. She explains why being an entrepreneur offers the best life balance for her and tips for all types of moms. Video provided by TheStreet
Powered by NewsLook.com
Catching More Than Fish: Ugandan Town Crippled by AIDS

Catching More Than Fish: Ugandan Town Crippled by AIDS

AFP (Apr. 22, 2014) The village of Kasensero on the shores of Lake Victoria was where HIV-AIDS was first discovered in Uganda. Its transient population of fishermen and sex workers means the nationwide programme to combat the virus has had little impact. Duration: 02:30 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins